Accelerating Cross-Sector Integration in Pharma and Nutraceuticals
Early-Phase Oncology Trials Shaping the Future of Cancer Research
From the “AI Pilot Graveyard” to Enterprise- Grade Impact
Tailored Artificial Intelligence (AI)
Relatively Speaking
EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
.webp)
KNOWLEDGE BANK
-
Articles
Unlocking Value: Data Science Applications in Pharmacoeconomics
In the realm of healthcare where every decision has significant financial implications pharmacoeconomics plays a pivotal role It involves the evaluation of the economic impact of pharmaceutical products and services
Post-Pandemic Trends: Reshaping the Future of European Pharma
The widespread influence of the COVID pandemic has deeply affected industries worldwide and the European pharmaceutical sector is no stranger to this impact This article delves into the lasting repercussions of the pandemic
Harnessing the Potential of mRNA Technology for Precision Cancer Treatment
Recent developments in medical research have highlighted the potential of mRNA as a viable approach for addressing challenges in healthcare particularly in combating infectious diseases and cancer
The Future of Oncology Clinical Trials: Adaptive, Biomarker-Led, and AI-Enabled
Oncology now absorbs close to a third of the industrys active development pipeline and a comparable share of its research budget It also carries the worst odds in medicine A molecule entering firstinhuman cancer studies has historically had a midsingledigit probability of reaching approval against roughly double that across other therapy areas For a European chief executive allocating capital acro...
Unlocking New Therapies: How Generative AI Enhances Drug Discovery
Drug discovery is a highly complex process that used to be very timeconsuming a decade or more for the entire project However Generative AI or Artificial Intelligence has brought significant shifts in the sector
Combination Immunotherapy Trials: Designing the Next Generation of Cancer Drugs
For most of the past ten years the prevailing strategy in immunooncology was addition Checkpoint blockade delivered durable remissions in a minority of patients the intuitive fix was to attach a second agent to a PD or PDL backbone and watch whether response rates moved
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Post-Pandemic Trends: Reshaping the Future of European Pharma
Kate Williamson
Examining the aftermath of the COVID-19 pandemic, this article delves into how the European pharmaceutical sector is transforming. Key trends include the integration of digital health, heightened focu...
-
2
Harnessing the Potential of mRNA Technology for Precision Cancer Treatment
Anindita Bag
Rahul Maheshwari
Approximately 11 months after the viral sequence was published, two mRNA-based SARS- CoV-2 vaccines received emergency approval, demonstrating the potential of the technology. Vaccines for cancer and...
-
3
The Future of Oncology Clinical Trials: Adaptive, Biomarker-Led, and AI-Enabled
Lakshmi
Oncology consumes the largest share of pharmaceutical R&D spend yet still carries the industry's steepest attrition curve. A structural shift is now under way: adaptive and platform designs re...
-
4
Unlocking New Therapies: How Generative AI Enhances Drug Discovery
Kate Williamson
The age of Generative AI is a major shift in drug discovery through speeding up development and improving the efficiency. This article is going to provide us with a critical analysis of how Generative...
-
5
Combination Immunotherapy Trials: Designing the Next Generation of Cancer Drugs
Lakshmi
Combination immunotherapy is now a portfolio necessity, yet late-stage combination trials in oncology continue to fail at an uncomfortable rate. This article examines why attaching a second immune tar...
press releases Read more...
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Fortrea a leading global contract research organization CRO and Omico Australias leading precision oncology screening and trial matching organization today announced a collaboration to accelerate precision oncology research by helping connect cancer patients to biomarkermatched clinical trials By co...
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
AstraZeneca today announced the US availability of ZEGFROVY sunvozertinib for the treatment of adults with locally advanced or metastatic nonsmall cell lung cancer NSCLC whose tumors have epidermal growth factor receptor EGFR exon insertion mutations as detected by an FDAapproved test
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
Cardiff Oncology Inc a clinicalstage biotechnology company leveraging PLK inhibition to develop novel cancer therapies today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
Geneos Therapeutics a clinical stage biotherapeutics company focused on the development of neoantigenbased personalized immunotherapy for cancer PIC today announced the initiation of its Phase randomized clinical trial NCT in patients with highrisk hepatocellular carcinoma HCC liver cancer
Events Read more...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026Pharma Manufacturing & Automation Convention 2026
Novotel Hyderabad Airport, Ind...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
LATEST NEWS Read more...
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
The Menarini Group a leading international pharmaceutical and diagnostics company and Stemline Therapeutics Inc Stemline a whollyowned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients along with Georgiamune Inc a clinicalstage biotechnology...
LGM Pharma Acquires Sannova Analytical, Expanding cGMP Analytical and GLP Bioanalytical Services
LGM Pharma a leading provider of tailored API sourcing contract analytical testing and drug development services today announced it has acquired Sannova Analytical a contract research laboratory headquartered in Somerset NJ The acquisition expands LGM Pharmas analytical testing services business by...
AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million
AI Proteins Inc a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC an affiliate of Astellas Pharma Inc TSE to discove...
Okomera Announces Trade Agreement with Servier to Use Tumor Miniaturization Technology in Cancer Research
Okomera a TechBio company that personalizes cancer management with its technology combining minivatars tumor microfluidics and AI imaging today announced the signing of a commercial agreement with Servier an independent international pharmaceutical group
ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
ScionxBio a privately held preclinicalstage biotechnology company pioneering nextgeneration mRNA therapeutics distinguished by their extended durability profile today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi
Takara Bio USA Partners with SPT Labtech to Deliver Automation-Ready NGS Library Preparation Technologies
Takara Bio USA Inc a wholly owned subsidiary of Takara Bio Inc and SPT Labtech today announced their partnership to deliver validated automated library preparation workflows that combine Takara Bio nextgeneration sequencing NGS library preparation chemistries with SPT Labtechs firefly liquid handlin...
